Jinwon Life Sciences Completes Enrollment of Participants for Phase 1 Clinical Trial of COVID-19 Vaccine
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 4th that it has completed the enrollment of a total of 45 participants for the Phase 1 clinical trial of the COVID-19 vaccine GLS-5310, currently underway at Korea University Guro Hospital.
The company stated, "The first dose has been completed for all participants in the Phase 1 clinical trial, and the second dose has begun," adding, "No serious adverse effects caused by the vaccine have been reported so far."
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Park Younggeun, CEO of GeneOne Life Science, said, "With the cooperation of Korea University Guro Hospital, the enrollment of all participants in the Phase 1 clinical trial has been completed," and added, "Our company is also conducting challenge infection animal experiments to evaluate whether GLS-5310, developed early to prepare for virus mutations, effectively responds to variants such as the South African virus."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
